Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
10.48
+0.13 (1.26%)
May 12, 2025, 2:23 PM - Market open
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change (1Y)
5
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,728,533
Market Cap
204.69M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACTU News
- 19 days ago - Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 25 days ago - Actuate to Present Promising Data on Elraglusib in Advanced Salivary Gland Carcinoma at the AACR Annual Meeting 2025 - GlobeNewsWire
- 3 months ago - Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer - GlobeNewsWire
- 6 months ago - Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development - GlobeNewsWire
- 8 months ago - Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma - GlobeNewsWire
- 8 months ago - Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 9 months ago - U.S. IPO Weekly Recap: WeRide Reschedules While 6 New Filers Join The Pipeline - Seeking Alpha